Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to the Costco Member ...

Celltrion announced on the 24th that its autoimmune disease treatment 'Steqeyma' is set to be sold at Costco, the third-largest major retailer in the United States. This comes about two weeks ...

Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatment that modify the natural history of knee osteoarthritis, announces that it has been authorized by Health ...

Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, PenetriumTM, showed significant anti-metastatic efficacy in a preclinical study ...

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to ...

With multiple entrants – including Stada’s Uzpruvo, Sandoz’s Pyzchiva, Celltrion’s Steqeyma, and Amgen’s Wezenla – clinicians may gravitate toward lower-cost alternatives, potentially ...

Samsung Bioepis was the first, launching Pyzchiva in the U.S. on Feb. 24. Celltrion and Dong-A ST have secured FDA approval for Steqeyma and Imuldosa, respectively, and plan to launch them later this ...